allcancercure.com

Doctors know that an impaired sense of smell is an early indicator of Parkinson’s Disease. Now they want to know if a smell test can help determine if people with no symptoms eventually develop the disease. “The analogy would be like diagnosing coronary artery disease before the heart attack,” says Dr. Kapil Sethi, director of [...]

Neurologix, Inc. (OTCBB:NRGX), a biotech company engaged in the research and development of innovative gene therapies for the brain and central nervous system, announced that the U.S. Food and Drug Administration has granted Fast Track Designation for the company’s experimental gene transfer procedure for the treatment of advanced Parkinson’s disease. The Neurologix procedure delivers a [...]

Allosteric modulation company Addex Pharmaceuticals (SWX:ADXN) announced that it has entered an exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd) with the goal of developing a new class of orally available drugs, initially as candidates for the treatment of Parkinson’s disease and potentially other [...]

Omega-3 fatty acids protect the brain against Parkinson’s disease, according to a study by Universite Laval researchers published in the online edition of the FASEB Journal, the journal of the Federation of American Societies for Experimental Biology. This study, supervised by Frederic Calon and Francesca Cicchetti, is the first to demonstrate the protective effect of [...]

New data from the first-ever clinical trial of a novel gene therapy for advanced Parkinson’s disease demonstrate the ability of Neurologix, Inc.’s (OTCBB:NRGX) gene transfer treatment to quiet the abnormal brain activity that is correlated with the motor deficits characterizing the disease. Details regarding the normalization of brain activity in treated patients, as measured through [...]

Brain scans used to track changes in a dozen patients who received an experimental gene therapy show that the treatment normalizes brain function — and the effects are still present a year later. Andrew Feigin, MD, and David Eidelberg, MD, of The Feinstein Institute for Medical Research collaborated with Michael Kaplitt, MD, of Weill Cornell [...]